Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden

When considering the cost-effectiveness categorization as proposed by the Swedish National Board of Health and Welfare, clopidogrel appears to be associated with costs per QALY that range from intermediate in the total CAPRIE population to low in high-risk atherosclerotic patients. </AbstractSection> Copyright Adis Data Information BV 2010

MoreLess

Year of publication:	2010
Authors:	Logman, J. ; Heeg, Bart ; Herlitz, Johan ; Hout, Ben
Published in:	Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 8.2010, 4, p. 251-265
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011000730